Carbaglu Does Not Set Precedent For Orphan Drugs To Skip Trials, FDA Says
Executive Summary
FDA is not setting a precedent by considering Orphan Europe's orphan drug Carbaglu for approval without a clinical trial, FDA's Office of Drug Evaluation III Director Julie Beitz indicated after the Endocrine and Metabolic Drugs Advisory Committee's Jan. 13 vote for approval
You may also be interested in...
CSL Behring's Corifact Clears FDA On 14-Patient Trial
The orphan drug, for a rare blood disorder, is the latest in a history of drugs for ultra-orphan conditions.
Rare Disease Drugs Need Faster Development Track, Sen. Brownback Tells FDA
Sen. Sam Brownback, R-Kansas, told FDA it should establish a second track for the development and approval of drugs for rare and neglected diseases
Rare Disease Drugs Need Faster Development Track, Sen. Brownback Tells FDA
Sen. Sam Brownback, R-Kansas, told FDA it should establish a second track for the development and approval of drugs for rare and neglected diseases